HYPERTENSION IN PATIENTS WITH SHY-DRAGER SYNDROME

[Shy-Drager syndrome].

Effect of xamoterol in Shy-Drager syndrome.

BACKGROUND Xamoterol, a cardioselective beta 1-adrenoceptor partial agonist, has been reported to be effective on postural hypotension. We investigated the effect of xamoterol in five patients with Shy-Drager syndrome (SDS) in relation to their prevailing sympathetic nerve activity and sensitivity of beta-adrenoceptors and the change in circadian variation of blood pressure. METHODS AND RESUL...

A case of Shy, Drager Syndrome

SUMMARY Shy, Drager syndrome is multi system degeneration of the central nervous system along with pandysautonomia. It begins after age 50 and affects men twice as women. The cardinal manifestation are due to basal ganglia and orthostatic hypotension. In spite of extrapyramidal involvement the response is poor to conventional anti-Parkinsonian medications and if this is the case in a middle ag...

Shy-Drager syndrome: recognition and management.

Shy-Drager syndrome is an uncommon disorder in which the patient experiences progressive autonomic failure. It is a multisystem degenerative disease that involves the central autonomic, cerebellar, basal ganglia, pyramidal, or spinal motor neurons. The mean age of onset is 55 years. A male predominance is noted, with a 2 or 3:1 ratio. About 11 percent of patients with orthostatic hypotension ha...

Speech symptoms associated with early signs of Shy Drager syndrome.

Speech disturbances reflecting impaired laryngeal control were found in ten patients whose autonomic dysfunction was associated with central neurological disease (Shy Drager Syndrome). In contrast, ten patients with progressive autonomic failure without evidence of CNS involvement had no difficulties on speech function tasks in comparison with normal controls. Presence of speech symptoms may ai...